News and events

IYUZEH™ (latanoprost ophthalmic solution) 0.005%, the first and only preservative-free formulation of latanoprost, the most prescribed prostaglandin F2α analogue (PGA), is now available in the U.S.

The Glaucoma Foundation, The Intrepid Eye Society, National Medical Association Ophthalmology Section, and Real World Ophthalmology Unite with Thea to Help Preserve Patient Eye Health WALTHAM, Mass., May 30, 2023 /PRNewswire/ — Thea Pharma Inc. (“Thea”), the U.S. subsidiary of Europe’s leading independent ophthalmic-focused pharmaceutical company, Laboratoires Théa, today announced the launch of the Preservative Freedom Coalition to raise awareness of unmet […]

Thea Portfolio of Products Acquired from Akorn are not Affected by this Recall WALTHAM, Mass., April 28, 2023 /PRNewswire/ — Thea Pharma Inc. (“Thea”), the U.S. subsidiary of Europe’s leading independent pharmaceutical company, Laboratoires Théa, dedicated to the research, development, and commercialization of ophthalmic products, is responding to the recent statement related to the Akorn […]

LEXINGTON, Massachusetts – March 3, 2023 – Thea Pharma, Inc. (“Thea”), the U.S. subsidiary of Europe’s leading independent pharmaceutical company, Théa, dedicated to the research, development, and commercialization of ophthalmic products, announced the presentation of Phase III data on IYUZEH (latanoprost ophthalmic solution) 0.005% by Jason Bacharach, MD at the 2023 American Glaucoma Society (AGS) […]

IYUZEH™ (latanoprost ophthalmic solution) 0.005% is the first and only preservative-free formulation of latanoprost, the most prescribed prostaglandin F2α analogue (PGA) in the United States LEXINGTON, Massachusetts – December 14, 2022 – Thea Pharma, Inc. (“Thea”), the U.S. subsidiary of Europe’s leading independent pharmaceutical company, Laboratoires Théa, dedicated to the research, development and commercialization of ophthalmic products, […]

Théa Pharma announced the availability of the iVIZIA line of over-the-counter (OTC) eye care products in the United States. The iVIZIA OTC product line includes lubricating eye drops, lubricating eye gel, and three options for daily hygiene of sensitive eyelids. iVIZIA eye drops offer preservative-free extended relief and ocular surface protection to patients with any type of […]

LEXINGTON, MASSACHUSETTS – March 9, 2022 – Théa Pharma Inc. (“Théa”), the US subsidiary of Europe’s leading independent pharmaceutical company specializing in the research, development and commercialization of eye care products, today announced the completion of its previously announced acquisition of seven branded ophthalmic products from Akorn Operating Company LLC. The transaction expands Théa’s role […]

CLERMONT-FERRAND, FRANCE – January 28, 2022 – Laboratoires Théa SAS (“Théa”), Europe’s leading independent pharmaceutical company specializing in the research, development, and commercialization of eye-care products, today announced an agreement to purchase seven branded ophthalmic products from Akorn Operating Company LLC. The transaction will make Théa a best-in-class provider of products designed to fill the […]

Théa, the leading European pharmaceutical group in ophthalmology (excluding the retina market), increases its research and clinical trials capacity by doubling its innovation space footprint at the headquarters in Clermont-Ferrand.

World Glaucoma Week (March 7-13) is a global initiative of the World Glaucoma Association (WGA) to raise awareness on glaucoma. Glaucoma is a chronic eye disease that has become the 2nd leading cause of blindness in the world.

The Théa Group has announced the appointment of Ms. Susan Benton as Country Manager for the US entity, Thea Pharma Inc. Ms. Benton is a senior executive with more than 25 years of global commercial and business development experience in ophthalmic pharmaceuticals.